Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
Blueprint Medicines (BPMC) Stock Price & Analysis
497 Followers
BPMC Stock Chart & Stats
Day’s Range$90.75 - $93.37
52-Week Range― - ―
Previous Close$93.1
Volume529.23K
Average Volume (3M)N/A
Market Cap
$5.69B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 02, 2024EPS Estimate
-$1.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$98.33Price Target Upside7.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
Blueprint Medicines News
PremiumCompany Announcements
Blueprint Medicines Divests GAVRETO Rights to RigelBulls Say, Bears Say
Bulls Say
Clinical TrialsThe upcoming Investigational New Drug application for BLU-808 and potential Phase 1 clinical trial demonstrate Blueprint's advancing expertise in mast cell biology and its commitment to addressing unmet medical needs.
Drug DevelopmentBlueprint Medicines Corporation's BLU-808 exhibits exceptional selectivity and potential for chronic urticaria, positioning it as a promising candidate in mast cell disorder treatments.
Financial PerformanceAnalyst reiterates a Buy rating on BPMC with a Market Outperform rating and a price target of $114, reflecting confidence in the company's revenue growth and stock potential.
Bears Say
Competitive ThreatCompetitive landscape shows other companies also developing mast cell-driven disease therapies, posing potential challenges to Blueprint's market position.
Financial PerformanceGavreto US sales have been disappointing (<$30mn annually).
Market ExpectationAnalysts expect Ayvakit peak sales will fall short of Blueprint’s $2 billion projection.
---
Ownership Overview
17.25% Insiders
46.14% Mutual Funds
17.36% Other Institutional Investors
19.24% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BPMC FAQ
What was Blueprint Medicines’s price range in the past 12 months?
Currently, no data Available
What is Blueprint Medicines’s market cap?
Currently, no data Available
When is Blueprint Medicines’s upcoming earnings report date?
Blueprint Medicines’s upcoming earnings report date is May 02, 2024 which is today.
How were Blueprint Medicines’s earnings last quarter?
Blueprint Medicines released its earnings results on Feb 15, 2024. The company reported -$1.82 earnings per share for the quarter, beating the consensus estimate of -$2.04 by $0.22.
Is Blueprint Medicines overvalued?
According to Wall Street analysts Blueprint Medicines’s price is currently Undervalued.
Does Blueprint Medicines pay dividends?
Blueprint Medicines does not currently pay dividends.
What is Blueprint Medicines’s EPS estimate?
Blueprint Medicines’s EPS estimate is -$1.67.
How many shares outstanding does Blueprint Medicines have?
Currently, no data Available
What happened to Blueprint Medicines’s price movement after its last earnings report?
Blueprint Medicines reported an EPS of -$1.82 in its last earnings report, beating expectations of -$2.04. Following the earnings report the stock price went up 14.023%.
Which hedge fund is a major shareholder of Blueprint Medicines?
Among the largest hedge funds holding Blueprint Medicines’s share is Woodline Partners LP. It holds Blueprint Medicines’s shares valued at 75M.
---
Blueprint Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$98.33 (7.65% Upside)
$98.33 (7.65% Upside)
Blogger Sentiment
Bullish
BPMC Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 144.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.37%
12-Months-Change
Fundamentals
Return on Equity
-157.13%
Trailing 12-Months
Asset Growth
-22.27%
Trailing 12-Months
Company Description
Blueprint Medicines
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
---
BPMC Company Deck
---
BPMC Earnings Call
Q4 2024
0:00 / 0:00
---
BPMC Stock 12 Months Forecast
Average Price Target
$98.33
▲(7.65% Upside)
Technical Analysis
Best Analysts Covering BPMC
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+14.47%
reiterated a buy rating 4 months ago
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +14.47% per trade.
---